SG10201706148WA - Administration of an anti-activin-a compound to a subject - Google Patents

Administration of an anti-activin-a compound to a subject

Info

Publication number
SG10201706148WA
SG10201706148WA SG10201706148WA SG10201706148WA SG10201706148WA SG 10201706148W A SG10201706148W A SG 10201706148WA SG 10201706148W A SG10201706148W A SG 10201706148WA SG 10201706148W A SG10201706148W A SG 10201706148WA SG 10201706148W A SG10201706148W A SG 10201706148WA
Authority
SG
Singapore
Prior art keywords
activin
administration
subject
compound
Prior art date
Application number
SG10201706148WA
Inventor
Huiquan Han
Christopher Michael Haqq
Isaac Ciechanover
Xiaolan Zhou
John Zhao-Nian Lu
Original Assignee
Santa Maria Biotherapeutics Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc, Amgen Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of SG10201706148WA publication Critical patent/SG10201706148WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
SG10201706148WA 2013-02-01 2014-02-03 Administration of an anti-activin-a compound to a subject SG10201706148WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759961P 2013-02-01 2013-02-01
US201361815220P 2013-04-23 2013-04-23

Publications (1)

Publication Number Publication Date
SG10201706148WA true SG10201706148WA (en) 2017-08-30

Family

ID=51263035

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505960VA SG11201505960VA (en) 2013-02-01 2014-02-03 Administration of an anti-activin-a compound to a subject
SG10201706148WA SG10201706148WA (en) 2013-02-01 2014-02-03 Administration of an anti-activin-a compound to a subject

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201505960VA SG11201505960VA (en) 2013-02-01 2014-02-03 Administration of an anti-activin-a compound to a subject

Country Status (15)

Country Link
US (3) US20150359850A1 (en)
EP (2) EP2951205B1 (en)
JP (1) JP2016508504A (en)
KR (1) KR20150136061A (en)
CN (1) CN105431455A (en)
AU (1) AU2014212014A1 (en)
CA (1) CA2899889A1 (en)
CL (1) CL2015002116A1 (en)
EA (1) EA201591423A1 (en)
HK (1) HK1218553A1 (en)
IL (1) IL240139A0 (en)
MX (1) MX2015009901A (en)
PH (1) PH12015501709A1 (en)
SG (2) SG11201505960VA (en)
WO (1) WO2014121221A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
TW201625675A (en) * 2014-06-13 2016-07-16 聖塔瑪麗亞生物治療公司 Formulated receptor polypeptides and related methods
KR20180006386A (en) * 2015-04-22 2018-01-17 얼라이브젠 유에스에이 인코포레이티드 Hybrid ACTRIIB Ligand Trap Protein for the Treatment of Novel Muscle Wasting Diseases
CN109069467B (en) * 2015-11-11 2022-11-04 诺华股份有限公司 Use of myostatin antagonists, combinations containing them and uses thereof
PE20191741A1 (en) 2017-04-05 2019-12-12 Symphogen As COMBINED THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
CN111787981A (en) 2018-03-01 2020-10-16 瑞泽恩制药公司 Method of altering body composition
WO2024108158A1 (en) * 2022-11-18 2024-05-23 Byomass Inc. Anti-activin a/b antibodies and uses thereof
CN116948028B (en) * 2023-09-20 2023-11-28 北京合源汇丰医药科技有限公司 Anti-inhibin antibody and application thereof

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646A (en) 1838-03-21 Improvement in furnaces for smelting iron with anthracite
US7947A (en) 1851-02-25 Bellows fob musical instruments
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (en) 1982-01-06 1983-07-13 Toray Ind Inc Photosensitive resin composition
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
JPH01171495A (en) 1987-12-25 1989-07-06 Ajinomoto Co Inc Monoclonal antibody and quantitative determination method using said antibody
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3218637B2 (en) 1990-07-26 2001-10-15 大正製薬株式会社 Stable aqueous liposome suspension
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (en) 1990-08-27 1999-10-06 株式会社ビタミン研究所 Multilamellar liposome for gene transfer and gene-captured multilamellar liposome preparation and method for producing the same
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
DK0672141T3 (en) 1992-10-23 2003-06-10 Immunex Corp Methods for Preparation of Soluble Oligomeric Proteins
DE69232604T2 (en) 1992-11-04 2002-11-07 City Of Hope Duarte ANTIBODY CONSTRUCTS
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69535641D1 (en) 1994-04-29 2007-12-27 Curis Inc Morphogenic protein-specific cell surface receptors and their uses
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT1129190E (en) 1998-11-13 2007-08-08 Immunex Corp Human tslp dna and polypeptides
DE60027135T2 (en) 1999-01-21 2007-01-11 Metamorphix, Inc. INHIBITORS FOR GROWTH DIFFERENTIATION FACTOR AND ITS APPLICATIONS
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
JP4487376B2 (en) 2000-03-31 2010-06-23 味の素株式会社 Kidney disease treatment
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
EP1406929A2 (en) 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR101304718B1 (en) 2002-12-20 2013-09-05 암겐 인코포레이티드 Binding agents which inhibit myostatin
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
UA85055C2 (en) 2003-06-02 2008-12-25 Уайт Use of myostatin (gdf8) inhibitor in conjunction with corticosteroid for treating neuromuscular disorder
PL3395338T3 (en) 2003-09-12 2019-10-31 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005051299A2 (en) 2003-11-19 2005-06-09 Dyax Corp. Metalloproteinase-binding proteins
CA2564538A1 (en) 2004-04-22 2005-12-01 Oregon Health And Science University Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
ES2400687T3 (en) 2004-04-23 2013-04-11 Amgen Inc. Sustained Release Formulations
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
BRPI0514253A (en) 2004-08-12 2008-06-03 Wyeth Corp combination therapy for diabetes, obesity and cardiovascular disease using compositions containing gdf-8 inhibitors
BRPI0516011A (en) 2004-09-24 2008-08-19 Amgen Inc modified fc molecules
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
ES2395953T3 (en) 2005-01-26 2013-02-18 Amgen Fremont Inc. Antibodies to interleukin-1 beta
US20090238820A1 (en) 2005-03-08 2009-09-24 Allan Corey M ANTI-MAdCAM ANTIBODY COMPOSITIONS
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
DOP2006000093A (en) 2005-04-25 2007-01-31 Pfizer ANTIBODIES AGAINST MYOSTATIN
PT2447283E (en) * 2005-09-07 2015-10-08 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1)
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (en) * 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TW202021980A (en) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (en) 2007-03-06 2017-03-11 安美基公司 Variant activin receptor polypeptides and uses thereof
EP2578684B1 (en) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
CN103877564A (en) * 2007-09-18 2014-06-25 阿塞勒隆制药公司 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2315602A4 (en) 2008-06-26 2011-11-02 Acceleron Pharma Inc Methods for dosing an actriib antagonist and monitoring of treated patients
TW201919685A (en) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 Use of GDF traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
BRPI0920962A2 (en) * 2008-11-26 2016-07-12 Amgen Inc activin receptor polypeptide variants and uses thereof
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
MA33279B1 (en) 2009-04-27 2012-05-02 Novartis Ag COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
WO2011031901A1 (en) 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
WO2011085165A2 (en) * 2010-01-08 2011-07-14 The Brigham And Women's Hospital, Inc. Ca-125 immune complexes as biomarkers of ovarian cancer
WO2011123691A1 (en) * 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
WO2012064771A1 (en) * 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
EP2793925B1 (en) * 2011-12-19 2019-03-20 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013106715A1 (en) * 2012-01-13 2013-07-18 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
EP3094751A4 (en) 2014-01-14 2017-06-07 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
TW201625675A (en) 2014-06-13 2016-07-16 聖塔瑪麗亞生物治療公司 Formulated receptor polypeptides and related methods

Also Published As

Publication number Publication date
CN105431455A (en) 2016-03-23
HK1218553A1 (en) 2017-02-24
US20200108085A1 (en) 2020-04-09
AU2014212014A1 (en) 2015-08-27
JP2016508504A (en) 2016-03-22
WO2014121221A8 (en) 2015-12-23
SG11201505960VA (en) 2015-08-28
EP3985024A1 (en) 2022-04-20
US20150359850A1 (en) 2015-12-17
WO2014121221A1 (en) 2014-08-07
CL2015002116A1 (en) 2016-05-27
EP2951205B1 (en) 2021-08-11
MX2015009901A (en) 2016-04-06
US11541070B2 (en) 2023-01-03
US20230201231A1 (en) 2023-06-29
IL240139A0 (en) 2015-09-24
CA2899889A1 (en) 2014-08-07
EP2951205A4 (en) 2016-09-07
KR20150136061A (en) 2015-12-04
EP2951205A1 (en) 2015-12-09
EA201591423A1 (en) 2016-01-29
PH12015501709A1 (en) 2015-10-19

Similar Documents

Publication Publication Date Title
EP2970081A4 (en) Salts of treprostinil
IL240139A0 (en) Administration of an anti-activin a compound to a subject
HUE042591T2 (en) Trk-inhibiting compound
GB201302368D0 (en) Compound
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
PL2984159T3 (en) Preparation of lactylates directly from oil
HK1219100A1 (en) Pyridinylpyrazoloquinoline compound
EP2964292A4 (en) Compound needle
EP2777425A4 (en) Bottom stop assembly of zipper fast to take off
GB2516136B (en) Colenterazine analogs
GB201317006D0 (en) Component for attaching to a wall
EP3023416A4 (en) Preparation of (-)-huperzine a
EP2947066A4 (en) Phenoxyalkylamine compound
EP2974723A4 (en) Application of phthalide compound
GB201400763D0 (en) Device for axial locking of a moving part with respect to a reference part
GB201300324D0 (en) Improvements to letter-plates
GB201307331D0 (en) Compound
HK1208864A1 (en) A preparation method of ecteinascidin-743 intermediate -743
GB201408643D0 (en) Compound
GB201316725D0 (en) Device to prevent loss of belongings
PL3071575T3 (en) Preparation of normorphinans
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling
GB201321316D0 (en) Pharmaceutical Compound
HU4588U (en) Aid to improve no-failure operation of delivery lines